clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastritis D005756 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Periodontitis D010518 22 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fan Y et al. High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. 2014 J Laryngol Otol pmid:24555753
Hanson KE et al. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? 2014 J. Clin. Microbiol. pmid:24554745
Almeida N et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. 2014 Helicobacter pmid:24506175
Lara-Martín PA et al. Occurrence, distribution and partitioning of nonionic surfactants and pharmaceuticals in the urbanized Long Island Sound Estuary (NY). 2014 Mar. Pollut. Bull. pmid:24467856
Markert C et al. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. 2014 Br J Clin Pharmacol pmid:23738582
Ueda Y et al. [Obstructive pneumonia and brain abscess due to Nocardia elegans in a patient with systemic lupus erythematosus]. 2014 Kansenshogaku Zasshi pmid:24974451
Negrín-González J et al. Psychiatric adverse reaction induced by clarithromycin. 2014 Eur Ann Allergy Clin Immunol pmid:24853570
Kurosaki Y et al. [Two cases of pulmonary Mycobacterium avium complex disease with resistance to clarithromycin]. 2014 Kekkaku pmid:24979948
Iwanaga K and Carter ER Mycobacterium abscessus complex lung infection in a toddler with a tracheostomy. 2014 Pediatr. Pulmonol. pmid:23460506
Schuhfried G et al. Gilles de la Tourette Syndrome caused by Mycoplasma pneumoniae successfully treated with macrolides. 2014 Klin Padiatr pmid:25153913
Oztürk K et al. Diagnosis of helicobacter pylori infection. 2014 Turk J Gastroenterol pmid:25141328
Heo J and Jeon SW [Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea]. 2014 Korean J Gastroenterol pmid:24651586
Kang BK et al. [New therapeutic strategies against Helicobacter pylori]. 2014 Korean J Gastroenterol pmid:24651587
Lee JY and Kim N [Future trends of Helicobacter pylori eradication therapy in Korea]. 2014 Korean J Gastroenterol pmid:24651589
Lee SH et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. 2014 Ann Lab Med pmid:24422193
Pathak V et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. 2014 Ann Am Thorac Soc pmid:24460438
Jesus FP et al. In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25001300
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Sugamata R et al. Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression. 2014 J. Antibiot. pmid:24496145
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Gisbert JP et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. 2014 Dig. Dis. Sci. pmid:24126798
Maurer FP et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. 2014 J. Antimicrob. Chemother. pmid:24500188
Kuroda H et al. [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin]. 2014 Gan To Kagaku Ryoho pmid:25248908
Bouricha M et al. Mycobacterium marinum infection following contact with reptiles: vivarium granuloma. 2014 Int. J. Infect. Dis. pmid:24530276
Peedikayil MC et al. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. 2014 PLoS ONE pmid:24465624
Yoshida N et al. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. 2014 BMC Pharmacol Toxicol pmid:24593851
Farley R et al. Antibiotics for bronchiolitis in children under two years of age. 2014 Cochrane Database Syst Rev pmid:25300167
McNicholl AG et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. 2014 Gut pmid:23665990
Karamanolis GP et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. 2014 Digestion pmid:25531953
Hemphill A et al. Treatment of echinococcosis: albendazole and mebendazole--what else? 2014 Parasite pmid:25526545
Kawai T et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). 2014 J. Gastroenterol. Hepatol. pmid:25521730
Srinarong C et al. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. 2014 Asian Pac. J. Cancer Prev. pmid:25520127
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Homma S et al. The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients. 2014 Int Heart J pmid:25297501
Renvoisé A et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. 2014 J. Clin. Microbiol. pmid:25274991
Tu S and Yang H [Progress in the treatment of Helicobacter pylori infection]. 2014 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:25269503
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
de Boer EM et al. [Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment]. 2014 Ned Tijdschr Geneeskd pmid:25159698
Lyons J et al. An unusual lung mass post stem cell transplantation. 2014 Transpl Infect Dis pmid:24995624
Lee JW et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. 2014 Scand. J. Gastroenterol. pmid:24988873
Rakici H et al. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. 2014 J Dig Dis pmid:24980811
Acosta CP et al. [Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia]. 2014 Biomedica pmid:24968047
Lee JW et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. 2014 Scand. J. Gastroenterol. pmid:24957849
Raffaldi I et al. An atypical deep neck infection in a two-year-old child. 2014 Infez Med pmid:24955801
Togami K et al. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. 2014 Biopharm Drug Dispos pmid:24801141
Bernut A et al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. 2014 Antimicrob. Agents Chemother. pmid:24798271
Adebisi AO and Conway BR Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. 2014 Int J Pharm pmid:24792977
Bolhuis MS et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. 2014 Eur. Respir. J. pmid:24791826
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Peretz A et al. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. 2014 J. Antibiot. pmid:24781955
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674
Skvarc M et al. Multi locus sequence typing (MLST) used as a tool to confirm the ability of susceptible Helicobacter pylori strains to gain resistance to clarithromycin during eradication therapy. 2014 Jan-Feb Hepatogastroenterology pmid:24895826
UÄŸurlu T et al. Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. 2014 Mar-Apr Acta Pol Pharm pmid:25272652
Picoli SU et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. 2014 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:24878996
Tongtawee T et al. Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. 2015 Asian Pac. J. Cancer Prev. pmid:26163609
Fujimura S et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. 2015 J. Infect. Chemother. pmid:26162777
Cavkaytar S et al. Clarithromycin regresses endometriotic implants in rat endometriosis model. 2015 J Obstet Gynaecol pmid:26156575
Bai P et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. 2015 J Dig Dis pmid:26147515
Nie W et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. 2015 Biomed Res Int pmid:26146620
Kozan G et al. Effect of systemic clarithromycin and prednisolone on histamine-induced otitis media in guinea pigs. 2015 Acta Otolaryngol. pmid:26143935
Ferro BE et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. 2015 J. Antimicrob. Chemother. pmid:26142475
Reveiz L and Cardona AF Antibiotics for acute laryngitis in adults. 2015 Cochrane Database Syst Rev pmid:26002823
Ahmed S and Atia NN Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. 2015 Spectrochim Acta A Mol Biomol Spectrosc pmid:25459696
Prapitpaiboon H et al. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26028098
Nayyar E and Taimur S Sporotrichoid lesions: an age-old conundrum. 2015 Am. J. Med. pmid:26021809
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Rose SJ et al. Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. 2015 PLoS ONE pmid:26010725
Kesselheim AS et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. 2015 J Gen Intern Med pmid:25855479
Gianni C Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. 2015 G Ital Dermatol Venereol pmid:25854670
Zhang S et al. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. 2015 Cancer Lett. pmid:25853150
Zhang S and Long C Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. 2015 J. Pediatr. Hematol. Oncol. pmid:25851555
Burton AJ et al. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. 2015 Antimicrob. Agents Chemother. pmid:25824218
Kazama I et al. Macroscopic haemoglobinuria associated with Mycoplasma pneumoniae infection successfully treated by clarithromycin. 2015 Infez Med pmid:25819056
Silva JT et al. Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review. 2015 Transpl Infect Dis pmid:25816889
Streetman DS and Stout SM Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? 2015 CMAJ pmid:25646282
Ang TL et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. 2015 J. Gastroenterol. Hepatol. pmid:25639278
Kimko H et al. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen. 2015 J Clin Pharmacol pmid:25639255
Berry AC et al. Not All Helicobacter Are pylori. 2015 Clin. Gastroenterol. Hepatol. pmid:25638590
Dinca EB et al. The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:25629665
Liu Q et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection. 2015 Eur J Gastroenterol Hepatol pmid:25629566
Galvidis I et al. Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes. 2015 Anal. Biochem. pmid:25256165
Siekmeier R et al. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. 2015 Adv. Exp. Med. Biol. pmid:25252902
Kim H et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 Ann. Hematol. pmid:25501820
Phan TN et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. 2015 Int. J. Antimicrob. Agents pmid:25499186
Adebisi AO et al. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. 2015 J. Pharm. Pharmacol. pmid:25496042
Jesus FP et al. In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. 2015 Antimicrob. Agents Chemother. pmid:26459895
Higuchi K et al. Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study. 2015 Gastric Cancer pmid:25098924
Chan CC et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. 2015 BMC Gastroenterol pmid:26635102
Hsu PI et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. 2015 Medicine (Baltimore) pmid:26632893
Basyigit S et al. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. 2015 Bosn J Basic Med Sci pmid:26614852
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Barni S et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. 2015 J Investig Allergol Clin Immunol pmid:25997306
Zhang W et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. 2015 Gut pmid:26338726
Fasciana T et al. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. 2015 J. Med. Microbiol. pmid:26338221
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Zhu YC et al. Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus. 2015 Mol. Cell. Probes pmid:26334290
Georgopoulos SD et al. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. 2015 Expert Opin Pharmacother pmid:26330278
Koide T et al. Analysis of Distribution of Ingredients in Commercially Available Clarithromycin Tablets Using Near-Infrared Chemical Imaging with Principal Component Analysis and Partial Least Squares. 2015 Chem. Pharm. Bull. pmid:26329859